Home » EC Awards Marketing Authorization to GSK’s Nucala
EC Awards Marketing Authorization to GSK’s Nucala
The European Commission has awarded British drugmaker GlaxoSmithKline marketing authorization for Nucala as an add-on treatment for severe refractory eosinophilic asthma in adults.
Nucala (mepolizumab) targets interleukin-5, a protein that aids in regulating the function of eosinophils.
The FDA approved Nucala on Nov. 4 as add-on maintenance treatment for severe asthma in patients 12 and older, and with an eosinophilic phenotype. The mAb is under regulatory review in Japan and other countries.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May